Table 3.
Baseline demographics and disease characteristics of post-AAP patients with T878A mutations at baseline corresponding to patients shown in Figure 2 (per Figure 2A–C) and progression on apalutamide (per Figure 2D)
| Patient | A (Pt ID#7) | B (Pt ID#8) | C (Pt ID#6) | D (Pt ID#9) |
|---|---|---|---|---|
| Age | 83 | 64 | 74 | 58 |
| Race | White | White | White | White |
| Baseline PSA (ng/ml) | 58.4 | 1315.2 | 64.1 | 12.0 |
| ECOG PS | 1 | 1 | 1 | 0 |
| Gleason score | 4+5 | 4+3 | 4+3 | N/A |
AAP, abiraterone acetate plus prednisone; ECOG PS, Eastern Cooperative Oncology Group performance status; PSA, prostate-specific antigen.